OBJECTIVE:To investigate the effectiveness and safety of Jiawei Xiaoyao pill(加味逍遥丸,JXP)in the treatment of symptoms associated with premenstrual syndrome(PMS).METHODS:A total of 144 regularly menstruating women w...OBJECTIVE:To investigate the effectiveness and safety of Jiawei Xiaoyao pill(加味逍遥丸,JXP)in the treatment of symptoms associated with premenstrual syndrome(PMS).METHODS:A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018,and randomized to receive either a JXP or a matching placebo(12 g/d,6 g twice a day)for 3 menstrual cycles.The primary indicator was the reduced Daily Record of Severity of Problems(DRSP)scores in the luteal phase after 3 months of treatment.The safety outcomes included clinical adverse events(AEs),adverse reactions(ARs),changes in vital signs,and laboratory tests.RESULTS:JXP surpassed the placebo in reducing DRSP scores(psychological/somatic dysfunction)in the luteal phase over 3 menstrual cycles of treatment(PFAS=0.002,PPPS=0.001).Additionally,there were no significant differences in the incidence of AEs,severe AEs,withdrawal due to AEs and ARs between the two groups(all P>0.05),and no clinically significant adverse medical events related to the test drug observed.CONCLUSIONS:JXP was superior to the placebo in relieving the symptoms associated with PMS,which signified that JXP may be effective,safe,and welltolerated as an alternative therapy.展开更多
Jiawei Xiaoyao San(JWXYS)has shown excellent clinical efficacy in anxiety disorder,but has not yet attracted widespread attention.The animal experiments,clinical trials and mechanism studies of JWXYS were reviewed in ...Jiawei Xiaoyao San(JWXYS)has shown excellent clinical efficacy in anxiety disorder,but has not yet attracted widespread attention.The animal experiments,clinical trials and mechanism studies of JWXYS were reviewed in this article,which may provide a reference for developing new anxiolytic drugs based on this prescription.The literature was searched in PubMed and CNKI and the documents written in English or with English abstracts were selected.JWXYS could reduce the anxiety symptoms of patients alone and reduce the adverse reactions when it is used in combination with other drugs in the clinic.In preclinical studies,JWXYS also showed therapeutic effects in reducing anxiety-like behavior.The mechanisms may include improving the hypothalamic–pituitaryadrenal(HPA)axis and hormone disorders,increasing neurotransmitter content,neurogenesis,and regulating the synthesis of related enzymes.This article shows that JWXYS could effectively treat anxiety disorders by regulating the central nervous system.In the future,with the participation of more researchers,it is expected to develop innovative drugs for the treatment of anxiety disorders based on JWXYS.展开更多
OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial...OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China.METHODS:Participants were randomized into the JWXY group or the sertraline group.Each group received JWXY treatment and sertraline placebo,or sertraline and JWXY placebo for 8 weeks.Main outcomes were measured using the Hamilton Depression Rating Scale (HAMD),Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale.RESULTS:JWXY and sertraline had the equivalent effect on HAMD at every interview point.JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week,HAMD sleep disturbance subscale scores at the 8th and 12th week,and HAMA somatic anxiety subscale scores at the 12th week.The rate of adverse events in the two groups was the same.CONCLUSION:For mild to moderate depression with anxiety symptoms,JWXY could be as effective as sertraline in alleviating depressive symptoms.For anxiety symptoms,JWXY may be effective more quickly and with longer lasting effects than sertraline.In particular,it may also improve quality of sleep and somatic anxiety symptoms.JWXY is safe and cheaper than conventional antidepressants,and may be the first alternative choice for depression with anxiety symptoms.展开更多
目的:探讨加味逍遥散对不同性别抑郁样大鼠的行为、肝脏组织转录组、下丘脑-垂体-肾上腺(HPA)轴相关基因的表达及性激素水平的调控作用。方法:以利血平腹腔注射构建不同性别抑郁大鼠模型,对照组和模型组、氟西汀组、加味逍遥散组分别予...目的:探讨加味逍遥散对不同性别抑郁样大鼠的行为、肝脏组织转录组、下丘脑-垂体-肾上腺(HPA)轴相关基因的表达及性激素水平的调控作用。方法:以利血平腹腔注射构建不同性别抑郁大鼠模型,对照组和模型组、氟西汀组、加味逍遥散组分别予蒸馏水、氟西汀、加味逍遥散灌胃给药,连续21 d。采用旷场试验检测大鼠抑郁样行为,RNA-seq进行肝脏组织转录组分析,real time RT-PCR检测海马组织的5-羟色胺转运体(5-HTT)、γ-氨基丁酸A型受体(GABA_(A)R)、γ-氨基丁酸B型受体(GABA_(B)R2)、乙酰胆碱脂酶(AChE)、谷氨酸受体(GluR2)mRNA表达水平,酶联免疫吸附试验检测大鼠血清卵泡刺激素(FSH)、雌二醇(E2)、睾酮(T)激素水平。结果:加味逍遥散有效改善雌性、雄性大鼠抑郁样行为(P<0.05);主要调控肝脏组织细胞色素P450(CYP)家族基因转录;显著降低雌性抑郁大鼠GABA_BR2、AChE基因和雄性抑郁大鼠5-HTT、GABA_AR、GABA_BR2、GluR2基因表达水平(P<0.05);显著升高雌性抑郁大鼠FSH、E2和雄性抑郁大鼠T激素水平(P<0.05)。结论:加味逍遥散调控肝脏组织转录组,通过HPA-HPG轴发挥疏肝解郁、养血调经作用,有效改善不同性别大鼠抑郁样行为。展开更多
文摘OBJECTIVE:To investigate the effectiveness and safety of Jiawei Xiaoyao pill(加味逍遥丸,JXP)in the treatment of symptoms associated with premenstrual syndrome(PMS).METHODS:A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018,and randomized to receive either a JXP or a matching placebo(12 g/d,6 g twice a day)for 3 menstrual cycles.The primary indicator was the reduced Daily Record of Severity of Problems(DRSP)scores in the luteal phase after 3 months of treatment.The safety outcomes included clinical adverse events(AEs),adverse reactions(ARs),changes in vital signs,and laboratory tests.RESULTS:JXP surpassed the placebo in reducing DRSP scores(psychological/somatic dysfunction)in the luteal phase over 3 menstrual cycles of treatment(PFAS=0.002,PPPS=0.001).Additionally,there were no significant differences in the incidence of AEs,severe AEs,withdrawal due to AEs and ARs between the two groups(all P>0.05),and no clinically significant adverse medical events related to the test drug observed.CONCLUSIONS:JXP was superior to the placebo in relieving the symptoms associated with PMS,which signified that JXP may be effective,safe,and welltolerated as an alternative therapy.
基金supported by the National Natural Science Foundation of China(No.81173541).
文摘Jiawei Xiaoyao San(JWXYS)has shown excellent clinical efficacy in anxiety disorder,but has not yet attracted widespread attention.The animal experiments,clinical trials and mechanism studies of JWXYS were reviewed in this article,which may provide a reference for developing new anxiolytic drugs based on this prescription.The literature was searched in PubMed and CNKI and the documents written in English or with English abstracts were selected.JWXYS could reduce the anxiety symptoms of patients alone and reduce the adverse reactions when it is used in combination with other drugs in the clinic.In preclinical studies,JWXYS also showed therapeutic effects in reducing anxiety-like behavior.The mechanisms may include improving the hypothalamic–pituitaryadrenal(HPA)axis and hormone disorders,increasing neurotransmitter content,neurogenesis,and regulating the synthesis of related enzymes.This article shows that JWXYS could effectively treat anxiety disorders by regulating the central nervous system.In the future,with the participation of more researchers,it is expected to develop innovative drugs for the treatment of anxiety disorders based on JWXYS.
文摘OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China.METHODS:Participants were randomized into the JWXY group or the sertraline group.Each group received JWXY treatment and sertraline placebo,or sertraline and JWXY placebo for 8 weeks.Main outcomes were measured using the Hamilton Depression Rating Scale (HAMD),Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale.RESULTS:JWXY and sertraline had the equivalent effect on HAMD at every interview point.JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week,HAMD sleep disturbance subscale scores at the 8th and 12th week,and HAMA somatic anxiety subscale scores at the 12th week.The rate of adverse events in the two groups was the same.CONCLUSION:For mild to moderate depression with anxiety symptoms,JWXY could be as effective as sertraline in alleviating depressive symptoms.For anxiety symptoms,JWXY may be effective more quickly and with longer lasting effects than sertraline.In particular,it may also improve quality of sleep and somatic anxiety symptoms.JWXY is safe and cheaper than conventional antidepressants,and may be the first alternative choice for depression with anxiety symptoms.
文摘目的:探讨加味逍遥散对不同性别抑郁样大鼠的行为、肝脏组织转录组、下丘脑-垂体-肾上腺(HPA)轴相关基因的表达及性激素水平的调控作用。方法:以利血平腹腔注射构建不同性别抑郁大鼠模型,对照组和模型组、氟西汀组、加味逍遥散组分别予蒸馏水、氟西汀、加味逍遥散灌胃给药,连续21 d。采用旷场试验检测大鼠抑郁样行为,RNA-seq进行肝脏组织转录组分析,real time RT-PCR检测海马组织的5-羟色胺转运体(5-HTT)、γ-氨基丁酸A型受体(GABA_(A)R)、γ-氨基丁酸B型受体(GABA_(B)R2)、乙酰胆碱脂酶(AChE)、谷氨酸受体(GluR2)mRNA表达水平,酶联免疫吸附试验检测大鼠血清卵泡刺激素(FSH)、雌二醇(E2)、睾酮(T)激素水平。结果:加味逍遥散有效改善雌性、雄性大鼠抑郁样行为(P<0.05);主要调控肝脏组织细胞色素P450(CYP)家族基因转录;显著降低雌性抑郁大鼠GABA_BR2、AChE基因和雄性抑郁大鼠5-HTT、GABA_AR、GABA_BR2、GluR2基因表达水平(P<0.05);显著升高雌性抑郁大鼠FSH、E2和雄性抑郁大鼠T激素水平(P<0.05)。结论:加味逍遥散调控肝脏组织转录组,通过HPA-HPG轴发挥疏肝解郁、养血调经作用,有效改善不同性别大鼠抑郁样行为。
